Turnstone rejigs staff and exec team, eases preclinical work as cash runs low
Just over a year after going public, Turnstone Biologics is axing staff, adjusting its leadership team and changing its pipeline focus to extend its cash …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
